Sign In
Buy OPRX
$4.95
-0.330 (-6.25%)
At Close: Jun 03, 2026
OptimizeRx Corp. (OPRX) Reports Q1 Loss, Tops Revenue Estimates
06:59pm, Wednesday, 10'th May 2023
OptimizeRx Corp. (OPRX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.01 per share a year ago.
OptimizeRx Has A Good Growth Path Ahead
05:16pm, Monday, 03'rd Apr 2023
OptimizeRx Corporation is an interesting company with an investment thesis based on its ability to capture a large TAM, with customers being some of the largest pharma companies out there. The company
OptimizeRx Corp. (OPRX) Soars 7.2%: Is Further Upside Left in the Stock?
04:37am, Wednesday, 15'th Mar 2023
OptimizeRx Corp. (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)
08:02am, Tuesday, 14'th Mar 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
OptimizeRx Corporation (OPRX) Q4 2022 Earnings Call Transcript
10:23pm, Wednesday, 08'th Mar 2023
OptimizeRx Corporation (NASDAQ:OPRX ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Will Febbo - CEO Ed Stelmakh - CFO and COO Steve Silvestro - Chief Commercial Offic
OptimizeRx Corp. (OPRX) Q4 Earnings Beat Estimates
06:48pm, Wednesday, 08'th Mar 2023
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 4.17% and 9.81%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy OptimizeRx (OPRX) Ahead of Earnings?
12:02pm, Thursday, 02'nd Mar 2023
OptimizeRx (OPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
OptimizeRx Sets Fourth Quarter & Fiscal Year 2022 Conference Call for March 8, 2023 at 4:30 p.m. ET
08:00am, Thursday, 23'rd Feb 2023
ROCHESTER, Mich., Feb. 23, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on t
Strength Seen in OptimizeRx Corp. (OPRX): Can Its 10.1% Jump Turn into More Strength?
11:01am, Thursday, 05'th Jan 2023 Zacks Investment Research
OptimizeRx Corp. (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near
Strength Seen in OptimizeRx Corp. (OPRX): Can Its 10.1% Jump Turn into More Strength?
07:32am, Thursday, 05'th Jan 2023
OptimizeRx Corp. (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near
OptimizeRx CEO Issues Open Letter to Shareholders Ahead of Presentation at J.P. Morgan Healthcare Conference
12:30pm, Wednesday, 04'th Jan 2023 GlobeNewswire Inc.
ROCHESTER, Mich., Jan. 04, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on
These small-cap stocks might make you the most money in 2023, based on two important data points
08:43pm, Saturday, 10'th Dec 2022 MarketWatch
Previous periods of low valuations have resulted in big comebacks for smaller companies.
OptimizeRx to Participate in Upcoming Investor Conferences
02:31pm, Monday, 28'th Nov 2022 GlobeNewswire Inc.
ROCHESTER, Mich., Nov. 28, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on
OptimizeRx to Participate in Upcoming Investor Conferences
09:31am, Monday, 28'th Nov 2022
ROCHESTER, Mich., Nov. 28, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on th
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
10:12am, Thursday, 10'th Nov 2022 Benzinga
Gainers
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares climbed 212.8% to close at $12.51 on Wednesday after partner Ipsen reported Onivyde met its primary and key secondary endpoint. Merrimac
